A Multi-Center, Randomized, Double-Blind, Parallel, Two-Group Phase III Trial on the Efficacy and Safety of QL1101 or Bevacizumab in Combination with Paclitaxel and Carboplatin in First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer.
Annals of Oncology（2019）
Key words
Microtubule-Targeting Agents
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined